Waltham,Mass.-based Avedro said it won CE Mark clearance in the European Union for its KXL II cross-linking system.
The technology uses a photorefractive intrastromal cross-linking procedure for non-surgical correction of myopia as well to improve cataract surgery outcomes, according to a company statement.
“The KXL II and PiXL procedure continue our mission to make refractive correction truly non-surgical," CEO David Muller said in prepared remarks. "Treating myopia and other refractive disorders with PiXL has the potential to open up refractive correction to millions of people who have never considered Lasik surgery before, but would consider a non-surgical alternative,”
Avedro landed $43 million in a funding round in March 2013, led by venture capital shops Third Point and Abingworth.